<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176239</url>
  </required_header>
  <id_info>
    <org_study_id>AHS1-13-003</org_study_id>
    <nct_id>NCT02176239</nct_id>
  </id_info>
  <brief_title>Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting</brief_title>
  <official_title>Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BriovaRx Infusion Services</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bio Products Laboratory (BPL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BriovaRx Infusion Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment&#xD;
      naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients&#xD;
      using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and&#xD;
      disability assessments using CareExchange in the home setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of collected data captured in CareExchange will demonstrate the ability to show and track changes in outcome data in 5% treatment naïve IVIg PIDD patients in the home setting.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the profile physician usage (dose and timing) with Gammaplex®.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate physician feedback to having real-time access to 5% treatment naïve IVIg PIDD data captured during home infusions.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile of using a 5% treatment naïve IVIg in PIDD patients in the home setting.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstration of response rate for those receiving IVIg therapies.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstration of changes in outcomes as a result of changes made in IVIg dose and frequency during study participation.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstration of measured variables within patients who receive IVIg therapies.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of whether CareExchange leads to better QOLs and overall patient reported outcomes.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other potential impacts on change in outcomes across patient demographics (age, sex, race, ethnicity, etc.).</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Primary Immunodeficiency Disease (PIDD)</condition>
  <arm_group>
    <arm_group_label>Gammaplex® IVIg</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Males and Females between 15-85 years of age with any form of PIDD who are considered 5%&#xD;
        IVIg treatment naïve and whose physician has decided to prescribe Gammaplex® IVIg therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any form of Primary Immunodeficiency Disease&#xD;
&#xD;
          -  Males and Females&#xD;
&#xD;
          -  ≥ 15 and ≤ 85 years of age&#xD;
&#xD;
          -  5% treatment Naïve IVIg for the treatment of PIDD&#xD;
&#xD;
          -  Ability to have Gammaplex® IVIg prescribed under the discretion of the patient's&#xD;
             treating physician in accordance with standard treatment practices for the entire&#xD;
             duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent and comply with study requirements&#xD;
             and procedures&#xD;
&#xD;
          -  Ability to read and write English&#xD;
&#xD;
          -  Understanding of study procedures and ability to comply with study procedures for the&#xD;
             entire length of the study&#xD;
&#xD;
          -  Eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration&#xD;
             with the subject's prescribing physician and insurance provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any medical condition that the investigator and/or prescribing&#xD;
             physician deems incompatible with participation in this trial.&#xD;
&#xD;
          -  Prisoners, and other wards of the state&#xD;
&#xD;
          -  Determined to have non-competency of data collection requirements (physical&#xD;
             assessments and use of an iPAD™) by either the home infusion nurse and/or Caregiver.&#xD;
&#xD;
          -  Receiving Subcutaneous Immunoglobulin (SCIg) Therapy during study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare)</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNEOe International Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta ENT</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AxelaCare Health Solutions, LLC</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

